Key result
First-line antihypertensive drug classes will be assessed for effectiveness compared to placebo or other classes in a planned Cochrane network meta-analysis protocol.
Why the study?
The study was designed to assess the effectiveness of different classes of drugs used as first-line antihypertensive therapy compared to placebo, no treatment, or an alternative first-line drug class.
Do different classes of drugs used as first-line antihypertensive therapy improve outcomes in adults with hypertension compared to placebo, no treatment, or a different first-line drug class?
Do different classes of drugs used as first-line antihypertensive therapy improve outcomes in adults with hypertension compared to placebo, no treatment, or a different first-line drug class?
This is a protocol for a network meta-analysis to evaluate the effectiveness of various first-line antihypertensive drug classes.
Answers are grounded in this paper and cite their sources.
Upcoming NMA may refine first-line antihypertensive selection; extends prior syntheses with comprehensive class comparisons.
Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: This systematic review with network meta‐analysis aims to assess the effectiveness of different classes of drugs used as first‐line antihypertensive therapy compared to placebo, no treatment, or a different first‐line drug class.
No takes yet. Share an insight, caveat, or question.
Lunny et al. (2020) studied this question. First-line antihypertensive drug classes will be assessed for effectiveness compared to placebo or other classes in a planned Cochrane network meta-analysis protocol.
Synapse has enriched 10 related papers. Consider them for comparative context: